Exploring disease-drug pairs in Clinical Trials information for personalized drug repurposing

被引:1
作者
Alvarez-Perez, Andrea, I [1 ,2 ]
Prieto-Santamaria, Lucia [1 ,2 ]
Ugarte-Carro, Esther [1 ]
Otero-Carrasco, Belen [1 ,2 ]
Ayuso-Munoz, Adrian [1 ,2 ]
Rodriguez-Gonzalez, Alejandro [1 ,2 ]
机构
[1] Univ Politecn Madrid, Ctr Tecnol Biomed, Madrid 28223, Spain
[2] Univ Politecn Madrid, ETS Ingenieros Intbrmat, Madrid 28660, Spain
来源
2023 IEEE 36TH INTERNATIONAL SYMPOSIUM ON COMPUTER-BASED MEDICAL SYSTEMS, CBMS | 2023年
关键词
Drug Repurposing; Clinical Trials; Precision Medicine; DISNET knowledge;
D O I
10.1109/CBMS58004.2023.00213
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Drug repurposing, the process of finding new uses for existing drugs, has gained considerable attention due to its potential to reduce the time and costs associated with drug development. Personalized drug repurposing, in which drugs are selected based on the characteristics of individual patients, is an emerging approach that holds promise for improving clinical outcomes. In this context, exploring disease-drug pairs in already conducted clinical trials can provide valuable insights to identify promising patient populations for further study that may lead to personalized drug repositioning. Our analysis aims to shed a light into clinical outcomes by selecting the most appropriate repurposed drug based on clinical trials patient groups' characteristics, such as age and gender. It also gives information about the state of the clinical trials studying these disease-drug pairs, gathering information about the study type, phase and statistical method used to calculate the p-value of the chosen outcome measurement, among others. Overall, this study highlights the importance of using existing knowledge as an initial framework to facilitate further research, particularly in providing patient-specific information. Furthermore, it underlines the importance of building on previous research to facilitate a comprehensive understanding of the research topic, which can eventually improve patient outcomes.
引用
收藏
页码:179 / 184
页数:6
相关论文
共 14 条
[1]   The Unified Medical Language System (UMLS): integrating biomedical terminology [J].
Bodenreider, O .
NUCLEIC ACIDS RESEARCH, 2004, 32 :D267-D270
[2]  
ClinicalTrials.gov, ClinicalTrials.gov background
[3]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[4]   ChEMBL: a large-scale bioactivity database for drug discovery [J].
Gaulton, Anna ;
Bellis, Louisa J. ;
Bento, A. Patricia ;
Chambers, Jon ;
Davies, Mark ;
Hersey, Anne ;
Light, Yvonne ;
McGlinchey, Shaun ;
Michalovich, David ;
Al-Lazikani, Bissan ;
Overington, John P. .
NUCLEIC ACIDS RESEARCH, 2012, 40 (D1) :D1100-D1107
[5]   Personalized medicine: motivation, challenges, and progress [J].
Goetz, Laura H. ;
Schork, Nicholas J. .
FERTILITY AND STERILITY, 2018, 109 (06) :952-963
[6]   DISNET: a framework for extracting phenotypic disease information from public sources [J].
Lagunes-Garcia, Gerardo ;
Rodriguez-Gonzalez, Alejandro ;
Prieto-Santamaria, Lucia ;
Garcia del Valle, Eduardo P. ;
Zanin, Massimiliano ;
Menasalvas-Ruiz, Ernestina .
PEERJ, 2020, 8
[7]   Drug repositioning for personalized medicine [J].
Li, Yvonne Y. ;
Jones, Steven J. M. .
GENOME MEDICINE, 2012, 4
[8]   Supersymmetric M-brane Solution in a Dynamical Background [J].
Maeda, Kengo ;
Uzawa, Kunihito .
GALAXIES, 2018, 6 (01)
[9]   The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics [J].
McLeod, HL ;
Siva, C .
PHARMACOGENOMICS, 2002, 3 (01) :89-98
[10]   Network pharmacology: curing causal mechanisms instead of treating symptoms [J].
Nogales, Cristian ;
Mamdouh, Zeinab M. ;
List, Markus ;
Kiel, Christina ;
Casas, Ana I. ;
Schmidt, Harald H. H. W. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (02) :136-150